Subcutaneous administration of bortezomib and its place in current myeloma therapy;Innovative substanzen und behandlungsmethoden beim multiplen myelom stellenwertder subkutanen bortezomib-cabe

Krankenhauspharmazie

Volumn 33, Issue 11, 2012, Pages 467-474

  Reinhardt, Heike ^a   Metzke, Barbara ^a   Udi, Josefina ^a   Kleber, Martina ^a   Engelhardt, Monika ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Bortezomib; Multiple myeloma; Oncology; Subcutaneous

Indexed keywords

BORTEZOMIB; LENALIDOMIDE; THALIDOMIDE;

BONE MARROW; CELL PROLIFERATION; COMORBIDITY; GERIATRIC PATIENT; GERMANY; HUMAN; LIFE EXPECTANCY; MULTIPLE MYELOMA; PLASMA CELL; REVIEW; STEM CELL TRANSPLANTATION; UNIVERSITY HOSPITAL;

EID: 84869853799     PISSN: 01737597     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Attal M, Lauwers-Cances V, Marit G, Caillot D, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1782-91.
2. Barlogie B, Anaissie E, van Rhee F, Haessler J, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007;138:176-85. (Pubitemid 46978271)
3. Bringhen S, Larocca A, Rossi D, Cavalli M, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010;116:4745-53.
4. Deschler B, de Witte T, Mertelsmann R, Lubbert M. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 2006;91:1513-22. (Pubitemid 44736118)
5. Dimopoulos M, Spencer A, Attal M, Prince HM, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-32. (Pubitemid 350146107)
6. Engelhardt M, Berger DP, Mertelsmann R. Das Blaue Buch. 4. Auflage. Berlin, Heidelberg: Springer Verlag, 2012.
7. Engelhardt M, Ihorst G, Behringer D, Finke J, et al. Incidence of monoclonal B-cell disease in siblings of patients with multiple myeloma. Haematologica 2006;91:274-6.
8. Engelhardt M, Kleber M, Frydrychowicz A, Pache G, et al. Superiority of magnetic resonance imaging over conventional radiographs in multiple myeloma. Anticancer Res 2009;29:4745-50.
9. Engelhardt M, Kleber M, Udi J, Wäsch R. Current approaches in multiple myeloma and other cancer-related bone diseases - from bisphosphonates through to targeted therapy. Dtsch Med Wochenschr 2012;137:1-6.
10. Engelhardt M, Kleber M, Udi J, Wasch R, et al. Consensus Statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma 2010;51:1424-43.
11. Fachinformation Bortezomib, Stand März 2012.
12. Fayers PM, Palumbo A, Hulin C, Waage A, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1,685 individual patient data from 6 randomized clinical trials. Blood 2011;118:1239-47.
13. Ferlay J, Shin HR, Bray F, Forman D, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
14. Harousseau JL, Dreyling M. Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(Suppl 2):ii55-7.
15. Hasskarl J, Ihorst G, De Pasquale D, Schrottner P, et al. Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma. Leuk Lymphoma 2011;52:247-59.
16. Jagannath S, Barlogie B, Berenson J, Siegel D, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-72. (Pubitemid 39371809)
17. Kleber M, Cybulla M, Bauchmuller K, Ihorst G, et al. Monitoring of renal function in cancer patients: an ongoing challenge for clinical practice. Ann Oncol 2007;18:950-8. (Pubitemid 47054095)
18. Kleber M, Ihorst G, Deschler B, Jakob C, et al. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. Eur J Haematol 2009;83:519-27.
19. Kleber M, Ihorst G, Terhorst M, Koch B, et al. Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer Journal 2011;1:e35.
20. Kleber M, Udi J, Metzke B, Terpos E, et al. Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy. Leuk Lymphoma 2012:53:1057-61.
21. Lyman GH, Dale DC, Friedberg J, Crawford J, et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004;22:4302-11. (Pubitemid 41185151)
22. Martinez-Lopez J, Blade J, Mateos MV, Grande C, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 2011;118:529-34.
23. Mateos MV, Lopez-Corral L, Hernandez M, et al. Smoldering multiple myeloma (SMM) at high-risk of progression to symptomatic disease: A phase III, randomized, multicenter trial based on lenalidomide-dexamethasone (Len-Dex) as induction therapy followed by maintenance therapy with Len alone vs no treatment. Blood (ASH Annual Meeting Abstracts) 2011;118:Abstract 991.
24. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770-81.
25. Moreau P. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies. Semin Hematol 2012;49(Suppl 1):S33-46.
26. Moreau P, Coiteux V, Hulin C, Leleu X, et al. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica 2008;93:1908-11.
27. Moreau P, Karamanesht I, Domnikova N, Kyselyova MY, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: Effects of subcutaneous injection site and concentration, and patient characteristics. Blood (ASH Annual Meetings Abstracts) 2011;118:Abstract 1863.
28. Moreau P, Pylypenko H, Grosicki S, Karamanesht E, et al. A phase 3 prospective randomized international study (MMY-3021) comparing subcutaneous and intravenous administration of bortezomib in patients with relapsed multiple myeloma. Blood (ASH Annual Meetings Abstracts) 2010;116:Abstract 312.
29. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12:431-40.
30. Morgan GJ, Davies FE, Gregory WM, Russell NH, et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 2011;118:1231-8.
31. Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011;117:4696-700.
32. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-60.
33. Palumbo A, Bringhen S, Rossi D, Cavalli M, et al. Bortezomib-melphalan- prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010;28:5101-9.
34. Palumbo A, Hajek R, Delforge M, Kropff M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366:1759-69.
35. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29-37.
36. Ries LAG MD, Krapcho M, Stinchcomb DG, Howlader N, et al. SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2005/. Based on November 2007 SEER data submission, posted to the SEER web site, 2008.
37. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17.
38. Sorror ML, Storer B, Storb RF. Validation of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in single and multiple institutions: limitations and inferences. Biol Blood Marrow Transplant 2009;15:757-8.
39. Weber DM, Chen C, Niesvizky R, Wang M, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-42. (Pubitemid 350146108)
40. Wedding U, Honecker F, Bokemeyer C, Pientka L, et al. Tolerance to chemotherapy in elderly patients with cancer. Cancer Control 2007;14:44-56. (Pubitemid 46168965)
41. Wedding U, Rohrig B, Klippstein A, Pientka L, et al. Age, severe comorbidity and functional impairment independently contribute to poor survival in cancer patients. J Cancer Res Clin Oncol 2007;133:945-50. (Pubitemid 47561710)
42. Wedding U, Wendt TG. Besonderheiten der Chemo- und Radiotherapie bei älteren Tumorpatienten und spezielle Aspekte der supportiven Therapie. Onkologie 2009;32(Suppl 3):24-8.
43. Witte J. De Witt M. Was tun wenn's brennt? Focus Onkologie 2010:50-5.
44. Wright JD, St. Clair CM, Deutsch I, Burke WM, et al. Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma. Cancer 2010;116:2486-92.